Form 4: Medtronic EVP Michael Marinaro Reports Changes in Beneficial Ownership

Medtronic's EVP & President, Surgical OU, Michael Marinaro, reports a transaction involving ordinary shares on March 5, 2024, including shares withheld for tax payments and shares acquired through dividend reinvestment.

Summary

• On March 5, 2024, Michael Marinaro, EVP & President, Surgical OU of Medtronic plc, reported a change in beneficial ownership of Medtronic's ordinary shares.
• 563 shares were disposed of to cover tax obligations related to the vesting of restricted stock units at a price of $83.6 per share.
• Marinaro's total holdings include 28,779 ordinary shares, which includes 412 shares acquired through dividend reinvestment since the last report.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment as it simply reports transactions related to executive stock ownership. The dividend reinvestment is a slightly positive signal.

Positives

• Marinaro increased his holdings by 412 shares through dividend reinvestment, indicating confidence in the company's future.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common for publicly traded companies like Medtronic. It provides transparency into the transactions of company insiders.

Comparison to Industry Standards

• Executive compensation practices, including stock-based compensation, are common across the medical device industry.
• Companies like Johnson & Johnson, Abbott Laboratories, and Stryker also utilize stock options and restricted stock units as part of their executive compensation packages.
• These practices are generally benchmarked against industry peers to attract and retain top talent.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders.
• It provides transparency to shareholders regarding executive stock ownership.

Key Dates